Format

Send to

Choose Destination
See comment in PubMed Commons below
HNO. 2007 Jun;55(6):457-64.

[New generation antihistamines as monotherapy or in combination. What is the relevance for daily clinical routine for allergic rhinoconjunctivitis].

[Article in German]

Author information

1
Institut für Medizinische Statistik, Informatik und Epidemiologie der Universität zu Köln (IMSIE), Kerpener Str. 62, 50937, Köln, Deutschland. ralph@moesges.de

Abstract

BACKGROUND:

The guidelines of German and European associations of allergology recommend the treatment of severe allergic rhinitis with a combination of oral antihistamines and nasal steroids. Many patients face this option rather skeptically, so that ENT specialists mostly use antihistamine monotherapy with a higher dosage. This increased dose may cause drowsiness, as has been demonstrated for cetirizine and loratadine. However, ebastine is a non-sedating antihistamine. Furthermore, it has been shown that improved clinical efficacy can be attained with an increased dosage of 20 mg daily in comparison to the usual dosage of 10 mg/day without increasing the rate of side effects.

METHODS:

In this prospective post-marketing survey, the treatment of 4,307 patients with allergic rhinitis was documented during the pollen season 2005. The severity of rhinitis symptoms and satisfaction with the treatment were recorded.

RESULTS:

Treatment with 20 mg ebastine daily as monotherapy led to a significantly greater reduction in symptoms (P=0.002) than the combination therapy.

CONCLUSION:

This outcome could be attributed to an assumed better compliance in patients with monotherapy.

PMID:
17566806
DOI:
10.1007/s00106-006-1509-1
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center